Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : I Will Continue to Continue, to Pretend.... -- Ignore unavailable to you. Want to Upgrade?

To: Sully- who wrote (14747)	10/5/2005 7:01:31 AM
From: Tadsamillionaire	Respond to of 35834

Flu Vaccines Losing Ability to Ward Off Disease" By Rob Stein, Washington Post Writer, Thur., Sept 22, 2005 In a new study published in the Lancet, flu vaccines appear to be significantly less effective among the elderly than had been believed. One reason for the diminished effect in preventing hospitalizations, researchers concluded, is that seniors' immune systems have been seriously eroded. In another study just out, a class of vaccines called adamantanes has registered a sudden jump in germ resistance... "We were alarmed to find such a dramatic increase in drug resistance in circulating human influenza viruses in recent years," Bright (Rick Bright of the U.S. CDC) said. washingtonpost.com TARVACIN's ANSWER TO ANTI-VIRAL DRUG RESISTANCE: ###Michael Brush in his 7-28-05 'Envelope Please' article, “A great thing about Thorpe’s approach is that viruses can’t mutate to fight off the Tarvacin attack. That’s because Tarvacin keys in on anomalies in the cell membrane – the confused phospholipids -- that viruses don’t know how to fix. ‘Since it’s not made by the virus, it is not mutable by the virus,’ says Peregrine CEO Steven King. ‘It is not something the virus can change, to get away from therapy.’” [ tinyurl.com ] ###Bernard Wolfson in his 7-16-05 O.C.R. 'High Hopes' article, “Scientists say Tarvacin could have an advantage over other anti-viral drugs because viruses probably won't be able to evade it by mutating. ‘Mutation won't affect it because it's targeting a substance which is not intrinsic to the virus itself but to the host cell - so that substance will be there no matter what new form the virus takes,’ says Dr. Stephen M. Smith, a paid Peregrine consultant and chief of infectious diseases at the Seton Hall School of Graduate Medical Education in Orange, NJ.” [ tinyurl.com ] ###CEO King 6-15-05, “Tarvacin recognizes a stable target common to all enveloped viruses that cannot easily be mutated because it is derived from the host, it's not encoded by the genome, but rather it's a stable structure of the virus particle.” [ tinyurl.com & tinyurl.com ] ###Virologist Dr. Stephen Smith (PPHM's SRB) 2-8-05: "I look forward to working [with Thorpe] on these novel anti-viral agents; this approach represents an entirely new way of combating infectious diseases. Instead of targeting viral proteins, Thorpe’s product attacks altered, endogenous phospholipids. Therefore, drug resistance cannot develop." ir.peregrineinc.com